STOCK TITAN

Corbus (NASDAQ: CRBP) director Anne Altmeyer receives RSU and stock option grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Corbus Pharmaceuticals Holdings, Inc. director Anne Altmeyer reported equity compensation awards. On May 19, 2026, she received 3,800 restricted stock units (RSUs) that will vest 100% one year from the grant date and be settled in common shares. She was also granted stock options on 12,300 shares of common stock at an exercise price of $9.15 per share, which will likewise vest 100% after one year. Following the RSU grant, she directly holds 9,991 shares of common stock, and the disclosure notes this amount includes 8,600 unvested RSUs subject to prior vesting schedules.

Positive

  • None.

Negative

  • None.
Insider Altmeyer Anne
Role null
Type Security Shares Price Value
Grant/Award Stock options (right to buy) 12,300 $0.00 --
Grant/Award Common Stock, par value $0.0001 per share 3,800 $0.00 --
Holdings After Transaction: Stock options (right to buy) — 12,300 shares (Direct, null); Common Stock, par value $0.0001 per share — 9,991 shares (Direct, null)
Footnotes (1)
  1. On May 19, 2026, 3,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant. This amount includes 8,600 unvested RSUs subject to each grant's vesting schedule as previously reported. The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant.
RSU grant size 3,800 RSUs Granted May 19, 2026; vest 100% after one year
Option grant size 12,300 options Granted May 19, 2026; underlying common stock
Option exercise price $9.15 per share Stock options on Corbus Pharmaceuticals common stock
Shares held after grant 9,991 shares Common stock directly held following RSU grant
Previously unvested RSUs 8,600 RSUs Unvested RSUs included in post-transaction holdings
restricted stock units ("RSUs") financial
"On May 19, 2026, 3,800 restricted stock units ("RSUs") were granted, which will be settled in shares"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
vesting schedule financial
"This amount includes 8,600 unvested RSUs subject to each grant's vesting schedule as previously reported"
A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.
Equity Compensation Plan financial
"The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan"
A plan by which a company gives employees, directors or contractors ownership or the right to buy ownership in the company through stock, options or similar awards — think of promising slices of the company pie as part of someone's pay. It matters to investors because these awards can change the number of shares outstanding, affect reported profits and influence management’s decisions; large or generous plans can dilute existing holders and alter incentives over time.
stock options (right to buy) financial
"Stock options (right to buy)"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Altmeyer Anne

(Last)(First)(Middle)
C/O CORBUS PHARMACEUTICALS HOLDINGS, INC
500 RIVER RIDGE DRIVE

(Street)
NORWOOD MASSACHUSETTS 02062

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Corbus Pharmaceuticals Holdings, Inc. [ CRBP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock, par value $0.0001 per share05/19/2026A3,800(1)A$09,991(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock options (right to buy)$9.1505/19/2026A12,300 (3)05/19/2026Common Stock12,300$012,300D
Explanation of Responses:
1. On May 19, 2026, 3,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.
2. This amount includes 8,600 unvested RSUs subject to each grant's vesting schedule as previously reported.
3. The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant.
/s/ Meghan Houghton, attorney-in-fact for Anne Altmeyer05/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Anne Altmeyer receive from Corbus Pharmaceuticals (CRBP)?

Anne Altmeyer received 3,800 restricted stock units and options on 12,300 shares. The RSUs settle in common stock, while the options allow future purchases at a fixed $9.15 exercise price, subject to vesting after one year.

When do Anne Altmeyer’s new RSUs and options in CRBP vest?

Both the 3,800 RSUs and the 12,300 stock options vest 100% on the one-year anniversary of the May 19, 2026 grant. Before vesting, she does not fully own the RSU shares or have exercisable rights to the options.

How many Corbus Pharmaceuticals (CRBP) shares does Anne Altmeyer hold after these grants?

After the May 19, 2026 grant, Anne Altmeyer directly holds 9,991 shares of CRBP common stock. This figure includes 8,600 previously granted unvested RSUs that remain subject to their individual vesting schedules as earlier disclosed.

What is the exercise price of Anne Altmeyer’s new Corbus Pharmaceuticals stock options?

The newly granted stock options cover 12,300 shares at an exercise price of $9.15 per share. This means she can purchase CRBP common stock at $9.15 once the options fully vest on the one-year anniversary of the grant date.

Under what plan were Anne Altmeyer’s Corbus Pharmaceuticals options granted?

The option award was granted under Corbus Pharmaceuticals’ 2024 Equity Compensation Plan. This plan governs how equity-based awards like stock options are issued to directors, including vesting terms and other conditions tied to the grant.